DiaMedica Inc. (TSX VENTURE:DMA) announces the commencement of its Phase I/II
trial with first in human dosing of DM-199; a recombinant protein therapy for
the treatment of diabetes and associated complications. As described in the
April 8th 2013 press release, the study is designed to evaluate the safety,
tolerability, pharmacokinetics and efficacy of DM-199 in 36 healthy volunteers
and in 40 Type 2 diabetic patients.


"The Phase I/II clinical trial will provide the opportunity to demonstrate the
safety and potential biological activity of DM-199 in healthy volunteers and
Type 2 diabetic patients during acute and longer-term use," stated Dr. Mark
Robbins, Vice President, Clinical & Regulatory Affairs. "With the promising
pre-clinical insulin sensitization and secretagogue activity of DM-199, we are
keen to assess the anti-diabetic activity in man."


"We are very pleased with the initiation of the clinical trial of DM-199," said
Rick Pauls, Chairman and CEO of DiaMedica. "We look forward to having the Phase
I and single dose Phase II results from the Phase I/II clinical trial in the
second half of 2013."


About DiaMedica  

DiaMedica Inc. is a publicly traded (TSX VENTURE:DMA) clinical stage
biopharmaceutical company focused on the discovery and development of novel
therapies to treat diabetes and the complications associated with diabetes.
DiaMedica's lead compound, DM-199, is a recombinant human protein that
represents a novel approach to treating Type 1 and Type 2 diabetes. Based on the
Company's understanding of the postprandial state, DiaMedica is also developing
a novel monoclonal antibody, DM-204 for the treatment of Type 2 diabetes.
Chronic treatment with DM-204 in a pre-clinical Type 2 diabetes model resulted
in a significant improvement in blood glucose control as measured by HbA1c and
also significant improved blood pressure and serum cholesterol levels.


The Company is listed on the TSX Venture Exchange in Canada under the trading
symbol 'DMA'.


FORWARD-LOOKING STATEMENTS

The statements made in this press release that are not historical facts contain
forward-looking information that involves risk and uncertainties. All
statements, other than statements of historical facts, which address DiaMedica's
expectations, should be considered forward-looking statements. Such statements
are based on management's exercise of business judgment as well as assumptions
made by and information currently available to management. When used in this
document, the words "may", "will", "anticipate", "believe", "estimate",
"expect", "intend" and words of similar import, are intended to identify any
forward-looking statements. You should not place undue reliance on these
forward-looking statements. These statements reflect a current view of future
events and are subject to certain risks and uncertainties as contained in the
Corporation's filings with Canadian securities regulatory authorities. Should
one or more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results could differ materially from those
anticipated in these forward-looking statements. The Corporation undertakes no
obligation, and does not intend, to update, revise or otherwise publicly release
any revisions to these forward-looking statements to reflect events or
circumstances after the date hereof, or to reflect the occurrence of any
unanticipated events. Although management believes that expectations are based
on reasonable assumptions, no assurance can be given that these expectations
will materialize.


FOR FURTHER INFORMATION PLEASE CONTACT: 
DiaMedica
Rick Pauls
Chairman & CEO
763-710-4455
info@diamedica.com
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more DiaMedica Inc. Charts.
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more DiaMedica Inc. Charts.